Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics, Inc. develops allogeneic T-cell immunotherapies through an Epstein-Barr virus (EBV) T-cell platform for cancer and autoimmune disease programs. Company news centers on tabelecleucel, also referred to as tab-cel or EBVALLO, regulatory communications with the FDA, and collaboration activity with Pierre Fabre Pharmaceuticals for the EBV-positive post-transplant lymphoproliferative disease program.
Recurring updates also cover financial results, commercialization revenue, research and development spending, operational efficiency measures, milestone and royalty-related agreements, and equity-linked financing instruments such as warrants. Atara also reports on its inventory-based cell therapy approach, platform attributes that avoid T-cell receptor or HLA gene editing, and pipeline candidates including ATA3431 and ATA3219.
Atara Biotherapeutics (Nasdaq: ATRA) reported second quarter 2026 results featuring an FDA Type A meeting that provided guidance for resubmission of the tabelecleucel (tab-cel) BLA based on the existing Phase 3 ALLELE trial with additional patients and longer follow-up.
Commercialization revenue was $0.6 million, down from $17.6 million a year earlier, primarily due to prior accelerated deferred revenue recognition. Net loss was $4.8 million versus net income of $2.4 million in Q2 2025. Cash, cash equivalents, and short-term investments totaled $9.9 million at June 30, 2026, and net cash used in operating activities declined to $3.3 million from $7.4 million.
Operating expenses, including R&D of $1.3 million and G&A of $3.8 million, fell sharply year-over-year, and Atara expects its current cash and efficiencies to fund operations into mid‑2027. The Pierre Fabre collaboration could yield a $31 million milestone upon potential FDA approval plus tiered royalties.
Atara Biotherapeutics (Nasdaq:ATRA) announced changes to its Board of Directors effective June 12, 2026. Long-time director Carol Gallagher, PharmD is departing after thirteen years of service, while private equity executive Brian Cherry joins the Board, bringing experience in capital allocation, strategic acquisitions, and multi‑sector investing.
Atara Biotherapeutics (Nasdaq:ATRA) reported first quarter 2026 results and regulatory progress on tab‑cel for PTLD.
The FDA agreed that a single‑arm ALLELE study with historical controls could support a BLA resubmission, with a further regulatory update expected in Q3 2026.
Cash, cash equivalents and short‑term investments were $8.4 million on March 31, 2026. Net cash used in operating activities fell to $3.1 million from $28.1 million a year earlier. Q1 2026 revenue was $0.5 million versus $98.1 million, which included a one‑time 2025 revenue acceleration.
Research and development expenses declined to $0.2 million, and general and administrative expenses to $3.6 million. Net loss was $4.1 million, or ($0.29) per share, compared with net income of $38.0 million in Q1 2025.
Atara expects existing cash plus $4.8 million of post‑quarter ATM proceeds and prior cost reductions to fund operations into mid‑2027.
Atara Biotherapeutics (Nasdaq: ATRA) reported a regulatory update on tabelecleucel (tab-cel) after a Type A meeting between the FDA and partner Pierre Fabre Pharmaceuticals. The FDA agreed a prospectively specified single‑arm study using an appropriate historical control could be adequate to support a resubmitted BLA.
Pierre Fabre intends to include an updated dataset with additional patients and longer follow‑up from the pivotal Phase 3 ALLELE study; Atara will support the resubmission and expects a further regulatory update in the third quarter.
Atara Biotherapeutics (Nasdaq: ATRA) reported fourth-quarter and full-year 2025 results and operational updates on March 16, 2026. The company reported $8.5 million in cash and short-term investments at Dec 31, 2025 and $120.8 million in 2025 commercialization revenue.
Atara posted a $32.7 million net income for FY2025 and expects its current resources plus $3.0 million ATM proceeds to fund operations through year-end 2026; a Type A meeting between Pierre Fabre and the FDA on tabelecleucel is scheduled with a regulatory update anticipated in Q2 2026.
Atara Biotherapeutics (Nasdaq: ATRA) said a Type A meeting with FDA has been scheduled to discuss the Complete Response Letter for the tabelecleucel (tab-cel) Biologics License Application held by partner Pierre Fabre Pharmaceuticals. Pierre Fabre, with Atara support, will seek to address CRL points and enable a BLA resubmission using additional efficacy data collected since the original submission. Atara expects to provide a further regulatory update in the second quarter.
Atara Biotherapeutics (NASDAQ: ATRA) said partner Pierre Fabre Pharmaceuticals submitted a request for a Type A meeting with the FDA on March 3, 2026 to address the Complete Response Letter dated January 9, 2026 for tabelecleucel (tab-cel).
The briefing book reportedly argues the ALLELE study was adequate and includes updated longer-term ALLELE efficacy data, additional supportive development data, and post-marketing data from Europe intended for a potential resubmission.
Atara Biotherapeutics (Nasdaq: ATRA) amended its December 2022 Purchase and Sale Agreement with a fund managed by HealthCare Royalty to push a one-time $9.0 million milestone cash payment from June 30, 2026 to January 1, 2028.
In connection with the amendment, Atara issued a warrant for up to 400,000 common shares at an exercise price of $0.0001 per share, exercisable immediately with no expiration and subject to a beneficial ownership limit. Management cites time to address a recent CRL and to support partner Pierre Fabre on tabelecleucel regulatory work.
Pierre Fabre Pharmaceuticals (collaborating on ATRA program) announced receipt of a Complete Response Letter (CRL) from the U.S. FDA on Jan 9, 2026, stating the tabelecleucel Biologics License Application cannot be approved in its present form.
The company says the FDA acknowledged resolution of a prior GMP deficiency but now requests a new study, reversing prior acceptance of the single‑arm ALLELE study and creating an unexpected change after multi‑year dialogue. Pierre Fabre intends to engage the FDA with Atara Biotherapeutics and continue expanded access while pursuing a path toward accelerated approval.
Atara Biotherapeutics (Nasdaq: ATRA) announced the FDA issued a Complete Response Letter (CRL) on Jan 9, 2026 for the EBVALLO™ (tabelecleucel) BLA for EBV+ PTLD, stating the ALLELE single‑arm trial is no longer adequate for accelerated approval despite prior FDA alignment; GMP issues were resolved and no safety concerns were raised. Atara transferred the BLA to Pierre Fabre Pharmaceuticals in Nov 2025; PFP plans a Type A meeting expected within 45 days to seek a path to accelerated approval. Financially, cash and equivalents were approximately $8.5M as of Dec 31, 2025; milestone payments under amended commercialization terms were adjusted to $31M plus a potential $15M contingent payment. Atara implemented ~90% headcount reduction in 2025 and reduced ARC lease liability by ~65%.